The Mitochondrial ubiquitin ligase MARCHF5 cooperates with MCL1 to inhibit Apoptosis in KSHV-transformed primary effusion lymphoma cell lines.

MARCHF5 and MCL1 cooperate to inhibit apoptosis in KSHV-transformed primary effusion lymphoma cells, with MARCHF5 promoting degradation of the pro-apoptotic protein NOXA.

• Why it matters: Understanding the mechanisms of apoptosis resistance in KSHV-associated cancers like primary effusion lymphoma is crucial for developing targeted therapies, especially since MCL1 is a key oncogene linked to chemotherapy resistance.
• What they did: Using a systems biology approach and CRISPR knockout experiments, the study revealed that MARCHF5 interacts with MCL1 and stabilizes NOXA, a pro-apoptotic factor, by promoting its degradation, thereby enhancing cell survival.
• The result: Disrupting MARCHF5 or stabilizing NOXA increases apoptosis, highlighting a potential therapeutic target to sensitize KSHV-related tumors to treatment by interfering with this pro-survival pathway.